Analysed RANI THERAPEUTICS HOLDINGS-A (RANI:NASDAQ) News Sources
Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
15-07-2026
yahoo.com
3 Small Cap Biotech Stocks Trading At A Discount With Late Stage Clinical Catalysts
28-08-2026
yahoo.com
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
09-04-2026
yahoo.com
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
12-05-2026
yahoo.com
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20-07-2026
yahoo.com
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline
16-08-2026
marketbeat.com
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules
26-05-2026
yahoo.com
What is the current price of RANI THERAPEUTICS HOLDINGS-A (RANI:NASDAQ)?
The current price of RANI THERAPEUTICS HOLDINGS-A (RANI:NASDAQ) is $0.84.
RANI THERAPEUTICS HOLDINGS-A (RANI:NASDAQ) absolute price change since previous trading day?
The absolute price change of RANI THERAPEUTICS HOLDINGS-A (RANI:NASDAQ) since the previous trading day is $-0.0142.
RANI THERAPEUTICS HOLDINGS-A (RANI:NASDAQ) percentage price change since previous trading day?
The percentage price change of RANI THERAPEUTICS HOLDINGS-A (RANI:NASDAQ) since the previous trading day is -1.6624%.
What is the most recent average sentiment score for RANI THERAPEUTICS HOLDINGS-A (RANI:NASDAQ)?
The most recent average sentiment score for RANI THERAPEUTICS HOLDINGS-A (RANI:NASDAQ) is 87 out of 100.
What is the most recent average sentiment for RANI THERAPEUTICS HOLDINGS-A (RANI:NASDAQ)?
The most recent sentiment for RANI THERAPEUTICS HOLDINGS-A (RANI:NASDAQ) is .
SEC-8K** Filing Available For RANI THERAPEUTICS HOLDINGS-A (RANI:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.